{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:32:38Z","timestamp":1740180758564,"version":"3.37.3"},"reference-count":23,"publisher":"Consilium Medicum","issue":"7","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 6070% of patients with chronic myeloid leukemia (CML). According to the current guidelines CML patients receive a long-term treatment with TKI in standard dose. The frequently observed adverse effects (AE) of TKI therapy are mostly dose-dependent. A new treatment approach with TKI use in reduced dose is desirable for the CML patients with existing AE or with a high risk of AE occurrence. We report the two cases of successful long-term treatment of CML patients with reduced doses of second generation TKIs. The aim of the TKI dose reduction was to reduce the clinical manifestations of drug toxicities and to prevent the AE.<\/jats:p>","DOI":"10.26442\/00403660.2020.07.000789","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T05:42:50Z","timestamp":1599889370000},"page":"90-94","source":"Crossref","is-referenced-by-count":1,"title":["Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review"],"prefix":"10.26442","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9984-389X","authenticated-orcid":false,"given":"M. A.","family":"Gurianova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-1789","authenticated-orcid":false,"given":"E. Yu.","family":"Chelysheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-0816","authenticated-orcid":false,"given":"O. A.","family":"Shukhov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-2371","authenticated-orcid":false,"given":"A. G.","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21320\/2500-2139-2017-10-3-390-401"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.253"},{"key":"ref4","unstructured":"\u0428\u0443\u0445\u043e\u0432 \u041e.\u0410., \u0422\u0443\u0440\u043a\u0438\u043d\u0430 \u0410.\u0413., \u0427\u0435\u043b\u044b\u0448\u0435\u0432\u0430 \u0415.\u042e. \u0438 \u0434\u0440. \u041e\u0442\u0434\u0430\u043b\u0435\u043d\u043d\u044b\u0435 \u0440\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u0438\u043d\u0433\u0438\u0431\u0438\u0442\u043e\u0440\u0430\u043c\u0438 \u0442\u0438\u0440\u043e\u0437\u0438\u043d\u043a\u0438\u043d\u0430\u0437 \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u043c\u0438\u0435\u043b\u043e\u043b\u0435\u0439\u043a\u043e\u0437\u043e\u043c \u0432 \u0440\u0430\u043d\u043d\u0435\u0439 \u0438 \u043f\u043e\u0437\u0434\u043d\u0435\u0439 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0444\u0430\u0437\u0435. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2016;9:368 [Shukhov OA, Turkina AG, Chelysheva EYu, et al. Long-term results of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients in early and late chronic phase. Klinicheskaya onkogematologiya. 2016;9:368 (In Russ.)]."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30192-X"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.2914"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"key":"ref8","unstructured":"Chelysheva E, Petrova A, Shukhov O, et al. First interim analysis of the russian multicenter prospective study ru-ski: discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia and deep molecular response. 23rd Congress of European Hematology Association. Hematologica. 2018;2(S1):PF374."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh2017891286-96"},{"key":"ref10","unstructured":"\u0417\u0435\u0439\u0444\u043c\u0430\u043d \u0410.\u0410., \u0427\u0435\u043b\u044b\u0448\u0435\u0432\u0430 \u0415.\u042e., \u0422\u0443\u0440\u043a\u0438\u043d\u0430 \u0410.\u0413., \u0427\u0438\u043b\u043e\u0432 \u0413.\u0413. \u0420\u043e\u043b\u044c \u0441\u0435\u043b\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u0438 \u0438\u043d\u0433\u0438\u0431\u0438\u0442\u043e\u0440\u043e\u0432 \u0442\u0438\u0440\u043e\u0437\u0438\u043d\u043a\u0438\u043d\u0430\u0437 \u0432 \u0440\u0430\u0437\u0432\u0438\u0442\u0438\u0438 \u043f\u043e\u0431\u043e\u0447\u043d\u044b\u0445 \u044d\u0444\u0444\u0435\u043a\u0442\u043e\u0432 \u043f\u0440\u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043c\u0438\u0435\u043b\u043e\u043b\u0435\u0439\u043a\u043e\u0437\u0430. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2014;7(1):16 [Zejfman AA, Chelysheva EYu, Turki- na AG, Chilov GG. Role of tyrosine-kinase inhibitor selectivity in development of adverse effects during treatment of chronic myeloid leukemia. Klinicheskaya onkogematologiya. 2014;7(1):16 (In Russ.)]."},{"key":"ref11","unstructured":"\u041b\u043e\u043c\u0430\u0438\u0430 \u0415.\u0413., \u0420\u043e\u043c\u0430\u043d\u043e\u0432\u0430 \u0415.\u0413., \u0421\u0431\u0438\u0442\u044f\u043a\u043e\u0432\u0430 \u0415.\u0418., \u0417\u0430\u0440\u0438\u0446\u043a\u0438\u0439 \u0410.\u042e. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0438 \u0431\u0435\u0437\u043e\u043f\u0430\u0441\u043d\u043e\u0441\u0442\u044c \u0438\u043d\u0433\u0438\u0431\u0438\u0442\u043e\u0440\u043e\u0432 \u0442\u0438\u0440\u043e\u0437\u0438\u043d\u043a\u0438\u043d\u0430\u0437 2-\u0433\u043e \u043f\u043e\u043a\u043e\u043b\u0435\u043d\u0438\u044f (\u0434\u0430\u0437\u0430\u0442\u0438\u043d\u0438\u0431, \u043d\u0438\u043b\u043e\u0442\u0438\u043d\u0438\u0431) \u0432 \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0444\u0430\u0437\u044b \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043c\u0438\u0435\u043b\u043e\u043b\u0435\u0439\u043a\u043e\u0437\u0430. \u041e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2013;2:22-33 [Lomaia EG, Romanova EG, Sbityakova EI, Zarickij AY. Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia. Onkogematologiya. 2013;2:22-33 (In Russ.)]."},{"key":"ref12","unstructured":"\u041b\u0430\u0437\u043e\u0440\u043a\u043e \u041d.\u0421., \u041b\u043e\u043c\u0430\u0438\u0430 \u0415.\u0413., \u0420\u043e\u043c\u0430\u043d\u043e\u0432\u0430 \u0415.\u0413. \u0438 \u0434\u0440. \u0418\u043d\u0433\u0438\u0431\u0438\u0442\u043e\u0440\u044b \u0442\u0438\u0440\u043e\u0437\u0438\u043d\u043a\u0438\u043d\u0430\u0437 \u0432\u0442\u043e\u0440\u043e\u0433\u043e \u043f\u043e\u043a\u043e\u043b\u0435\u043d\u0438\u044f \u0438 \u0438\u0445 \u0442\u043e\u043a\u0441\u0438\u0447\u043d\u043e\u0441\u0442\u044c \u0443 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u0432 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0444\u0430\u0437\u0435 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043c\u0438\u0435\u043b\u043e\u043b\u0435\u0439\u043a\u043e\u0437\u0430. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2015;8(3):302-8 [Lazorko NS, Lomaia EG, Romanova EG, et al. Second generation tyrosine kinase inhibitors and their toxicity in treatment of patients in chronic phase of chronic myeloid leukemia. Klinicheskaya onkogematologiya. 2015;8(3):302-8 (In Russ.)]."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24504"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.032"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18705\/1607-419X-2017-23-2-160-171"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.8899"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21320\/2500-2139-2019-12-2-194-201"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30066-2"},{"key":"ref21","unstructured":"Rea D, Cayuela J, Dulucq S, Etienne G. Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED). Blood. 2017;130(1):318. 590th ASH, Atlanta."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30094-8"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32504"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/43131\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/43131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:39:57Z","timestamp":1634157597000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/43131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2020.07.000789","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}